Abstract
Aberrant Hedgehog (Hh) signaling plays an important role in the pathogenesis and maintenance of many cancers. The mechanisms by which this pathway contributes to tumor progression are only now being unraveled. There appear to be two distinct ways by which Hh signaling becomes constitutively activated in tumors: by over expression of the ligand itself, or by acquisition of mutations in Hh signaling components at or downstream of the Hh receptor. The goal of this review is to briefly present the key components of the Hh pathway, and then discuss the known inhibitors of this pathway. We will describe how each inhibitor was identified, what is known of its mechanism of action, and its potential as a therapeutic agent against tumors dependent on Hh signaling.
Keywords: hedgehog, cancer, cyclopamine, inhibitors, review
Current Cancer Therapy Reviews
Title: Inhibitors of the Hedgehog Signal Transduction Pathway
Volume: 1 Issue: 3
Author(s): David J. Robbins, John A. Goetz, Ziqiang Yuan and Melanie A. Stegman
Affiliation:
Keywords: hedgehog, cancer, cyclopamine, inhibitors, review
Abstract: Aberrant Hedgehog (Hh) signaling plays an important role in the pathogenesis and maintenance of many cancers. The mechanisms by which this pathway contributes to tumor progression are only now being unraveled. There appear to be two distinct ways by which Hh signaling becomes constitutively activated in tumors: by over expression of the ligand itself, or by acquisition of mutations in Hh signaling components at or downstream of the Hh receptor. The goal of this review is to briefly present the key components of the Hh pathway, and then discuss the known inhibitors of this pathway. We will describe how each inhibitor was identified, what is known of its mechanism of action, and its potential as a therapeutic agent against tumors dependent on Hh signaling.
Export Options
About this article
Cite this article as:
Robbins J. David, Goetz A. John, Yuan Ziqiang and Stegman A. Melanie, Inhibitors of the Hedgehog Signal Transduction Pathway, Current Cancer Therapy Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339405774574243
DOI https://dx.doi.org/10.2174/157339405774574243 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Selenium Compounds Biotransformed by Mushrooms: Not Only Dietary Sources, But Also Toxicity Mediators
Current Nutrition & Food Science Breast Cancer: Not Only a “Womans” Disease
Current Women`s Health Reviews The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Impaired Expression and Function of Cancer-Related Enzymes by Anthocyans: An Update
Current Enzyme Inhibition Efalizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy Cancer Metastasis: Characterization and Identification of the Behavior of Metastatic Tumor Cells and the Cell Adhesion Molecules, including Carbohydrates
Current Drug Targets - Cardiovascular & Hematological Disorders Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry Breast Cancer Image Classification: A Review
Current Medical Imaging Key Questions in Metastasis: New Insights in Molecular Pathways and Therapeutic Implications
Current Pharmaceutical Biotechnology Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
Current Pharmaceutical Design Interaction of Drug or Food with Drug Transporters in Intestine and Liver
Current Drug Metabolism Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection
Reviews on Recent Clinical Trials The Molecular Pathology of Eye Tumors: A 2019 Update Main Interests for Routine Clinical Practice
Current Molecular Medicine Recent Patents in Autophagy and Immune Response
Recent Patents on Inflammation & Allergy Drug Discovery PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo
Current Drug Metabolism Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?
Current Neuropharmacology Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
Current Medicinal Chemistry Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Potential Therapeutic Applications of MDA-9/Syntenin-NF-κB-RKIP Loop in Human Liver Carcinoma
Current Molecular Medicine